Singapore vs Zimbabwe: Pneumococcal conjugate second or third-dose vaccines (PCVc)
Singapore
91.0%
in 2025
Zimbabwe
91.0%
in 2025
Singapore rank
59th
Zimbabwe rank
59th
Pneumococcal conjugate second or third-dose vaccines (PCVc) over time
- Singapore
- Zimbabwe
How they compare
Singapore currently reports 91.0% against 91.0% in Zimbabwe, a difference of 0.0%.
The two have swapped places 6 times across 18 shared years of data; in 2008 it was Zimbabwe ahead.
Singapore ranks 59th and Zimbabwe ranks 59th of 192 countries.
Across the 3 decades both report, Singapore averaged higher in 2 and Zimbabwe in 1.
Head to head by decade
| Decade | Singapore | Zimbabwe | Difference | Ahead |
|---|---|---|---|---|
| 2000s | 8.5% | 0.0% | 8.5% | Singapore |
| 2010s | 64.6% | 65.2% | 0.6% | Zimbabwe |
| 2020s | 90.0% | 89.3% | 0.7% | Singapore |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher pneumococcal conjugate second or third-dose vaccines (pcvc), Singapore or Zimbabwe?
- Singapore, at 91.0% against 91.0% in Zimbabwe as of 2025.
- What is the difference in pneumococcal conjugate second or third-dose vaccines (pcvc) between Singapore and Zimbabwe?
- 0.0%, with Singapore ahead.
- How many years of comparable data are there for Singapore and Zimbabwe?
- 18 years are reported by both, from 2008 to 2025.
- How do Singapore and Zimbabwe rank globally for pneumococcal conjugate second or third-dose vaccines (pcvc)?
- Singapore ranks 59th and Zimbabwe ranks 59th of 192 countries.
- Where does this data come from?
- World Health Organization, Global Health Observatory, published as Pneumococcal conjugate second or third-dose vaccines (PCVc) immunization coverage by the locally recommended age (%) (WUENIC). Statizoid refreshes it automatically from the source and publishes the full history for both places.